These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21292818)

  • 1. Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells.
    Aguilera R; Saffie C; Tittarelli A; González FE; Ramírez M; Reyes D; Pereda C; Hevia D; García T; Salazar L; Ferreira A; Hermoso M; Mendoza-Naranjo A; Ferrada C; Garrido P; López MN; Salazar-Onfray F
    Clin Cancer Res; 2011 Apr; 17(8):2474-83. PubMed ID: 21292818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
    López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
    J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
    J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
    Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
    Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
    de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ
    Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients.
    Tittarelli A; González FE; Pereda C; Mora G; Muñoz L; Saffie C; García T; Díaz D; Falcón C; Hermoso M; López MN; Salazar-Onfray F
    Cancer Immunol Immunother; 2012 Nov; 61(11):2067-77. PubMed ID: 22552381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor cell lysates as immunogenic sources for cancer vaccine design.
    González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
    Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy.
    González FE; Chernobrovkin A; Pereda C; García-Salum T; Tittarelli A; López MN; Salazar-Onfray F; Zubarev RA
    J Immunol Res; 2018; 2018():3982942. PubMed ID: 29744371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes.
    von Euw EM; Barrio MM; Furman D; Bianchini M; Levy EM; Yee C; Li Y; Wainstok R; Mordoh J
    J Transl Med; 2007 Apr; 5():19. PubMed ID: 17448240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens.
    Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD
    Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer.
    Salazar-Onfray F; Pereda C; Reyes D; López MN
    Biol Res; 2013; 46(4):431-40. PubMed ID: 24510145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.
    Van Nuffel AM; Tuyaerts S; Benteyn D; Wilgenhof S; Corthals J; Heirman C; Neyns B; Thielemans K; Bonehill A
    J Immunol Methods; 2012 Mar; 377(1-2):23-36. PubMed ID: 22269772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of transfection with total RNA of K562 cells upon antigen presenting, maturation, and function of human dendritic cells from peripheral blood mononuclear cells.
    Gao L; Fan HH; Lu HZ; Nie XX; Liu Y; Yang YM; Qian KC; Gao F
    Transfusion; 2007 Feb; 47(2):256-65. PubMed ID: 17302772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.
    Zappasodi R; Pupa SM; Ghedini GC; Bongarzone I; Magni M; Cabras AD; Colombo MP; Carlo-Stella C; Gianni AM; Di Nicola M
    Cancer Res; 2010 Nov; 70(22):9062-72. PubMed ID: 20884630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal Ag engrafted with peptides of sequence derived from HMGB1 induce potent Ag-specific and anti-tumour immunity.
    Faham A; Bennett D; Altin JG
    Vaccine; 2009 Sep; 27(42):5846-54. PubMed ID: 19660589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
    Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.